HC Wainwright & Co. maintains Buy rating on TriSalus Life Sciences, $12 price target
HC Wainwright & Co. maintained their Buy rating on TriSalus Life Sciences's stock with a price target of $12.00.The price target implies an upside of 143.4% from the Sep 22 close of $4.93.Key takeaways from the analyst noteExpansion of Market Opportunities: TriSalus Life Sciences has received FDA a…